Hydrocortison Activase (Hydrocortisone)

Hydrocortison Activase, as an oral hydrocortisone preparation, is employed in clinical practice for several glucocorticoid‑related indications.

• Replacement therapy for adrenal insufficiency (e.g., primary or secondary adrenal failure).
• Management of acute inflammatory episodes such as severe allergic reactions.
• Adjunct treatment for autoimmune disorders requiring systemic immunosuppression.
• Short‑term therapy for exacerbations of chronic inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis).

• Hydrocortison Activase exerts its pharmacologic effect by binding to intracellular glucocorticoid receptors, forming a receptor‑ligand complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements on DNA, modulating transcription of multiple genes. The resulting actions include reduced synthesis of prostaglandins and leukotrienes, inhibition of cytokine production, and suppression of immune cell activation, collectively diminishing inflammation and immune responses.

Oral hydrocortisone may be associated with a range of adverse reactions, which vary in frequency and severity.

Common

• Increased appetite or weight gain.
• Mild gastrointestinal discomfort such as nausea or dyspepsia.
• Fluid retention leading to peripheral edema.
• Mood changes including irritability or anxiety.

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus.
• Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis causing adrenal crisis on abrupt withdrawal.
• Opportunistic infections due to immunosuppression.

Before initiating Hydrocortison Activase, clinicians should evaluate several safety considerations to minimize risk.

• Assess for active infections; glucocorticoids can exacerbate bacterial, viral, or fungal diseases.
• Screen for diabetes or impaired glucose tolerance, as therapy may raise blood sugar levels.
• Evaluate bone health, especially in patients at risk for osteoporosis or fractures.
• Consider potential psychiatric effects, including mood swings or psychosis, particularly in high‑dose regimens.
• Use the lowest effective dose for the shortest duration necessary to reduce systemic exposure.
• Counsel patients on the need for gradual tapering when discontinuing long‑term therapy.

Hydrocortison Activase can interact with other medicines, altering its efficacy or increasing the risk of adverse events.

Avoid

• Strong CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) that may reduce hydrocortisone plasma concentrations.
• Concurrent use with other systemic glucocorticoids, which can amplify immunosuppressive and metabolic effects.

Use with caution

• Antidiabetic agents, as hydrocortisone may increase blood glucose and require dose adjustments.
• Anticoagulants (e.g., warfarin), because glucocorticoids can affect coagulation parameters.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which together may raise the risk of gastrointestinal ulceration.
• Vaccines, particularly live attenuated vaccines, due to possible reduced immune response.